| P/E (FY) | — | Sales (TTM) | $0 |
| Earnings (TTM) | -$68.2M | ROE | −41.29% |
| Net Margin | — | ROIC | — |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | — |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing antibody-based therapeutics in the United States. Its lead candidate, tovecimig, is a bispecific antibody targeting DLL4 and VEGF-A involved in angiogenesis and tumor vascularization. The pipeline also includes CTX-471, a CD137 agonist; CTX-8371, a PD-1 and PD-L1 bispecific inhibitor; and CTX-10726, a PD-1 and VEGF-A bispecific antibody.
| Market Cap | $367.4M | Trading Days | 1283 |
| 52W High | 6.88 |
| 52W Low | 1.61 |
| % Off High | −70.35% |
| YTD | −62.01% | 1Y | −36.25% |
| 3Y | −23.60% | 5Y | −55.65% |
| Since incept. (ann.) | −23.56% |
| Ann. Volatility (1Y) | 92.19% | Ann. Volatility (3Y) | 88.84% |
| Sharpe (1Y) | 0.16 | Sharpe (3Y) | 0.43 |
| Max Drawdown (1Y) | −75.04% | Max Drawdown (3Y) | −75.04% |
| Beta (3Y, vs SPY) | 1.27 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| IPSC | Century Therapeutics, Inc. | $369.7M | — |
| XFOR | X4 Pharmaceuticals, Inc | $370.7M | — |
| PALI | PALISADE BIO, INC. | $350.6M | — |
| AUTL | Autolus Therapeutics plc | $385.9M | — |
| FENC | FENNEC PHARMACEUTICALS INC. | $345.3M | — |
| LXEO | Lexeo Therapeutics, Inc. | $344.7M | — |
| CCCC | C4 Therapeutics, Inc. | $392.5M | — |
| STRO | SUTRO BIOPHARMA, INC. | $393.2M | — |
| OCGN | Ocugen, Inc. | $419.8M | — |
| DNA | Ginkgo Bioworks Holdings, Inc. | $427.0M | — |
| NMRA | Neumora Therapeutics, Inc. |
| $307.6M |
| — |
| IKT | Inhibikase Therapeutics, Inc. | $305.0M | — |
